News coverage about Ovid Therapeutics (NASDAQ:OVID) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ovid Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.3593030763878 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Ovid Therapeutics (NASDAQ:OVID) traded down $0.05 during mid-day trading on Monday, hitting $9.64. 117,700 shares of the company traded hands, compared to its average volume of 60,250. Ovid Therapeutics has a twelve month low of $5.28 and a twelve month high of $15.93.
Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.16. analysts anticipate that Ovid Therapeutics will post -4.08 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2018/01/08/ovid-therapeutics-ovid-earning-somewhat-positive-media-coverage-analysis-finds.html.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.